Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A mixed epithelial and mesenchymal neoplasm that arises from the cervix and is characterized by the presence of malignant mesenchymal elements and benign or malignant epithelial elements. This category includes adenosarcoma and carcinosarcoma.
No clinical trials have been registered for cervical carcinosarcoma.
9 publications have been identified in PubMed for cervical carcinosarcoma. Research spans Case Report / Case Series (44%), Epidemiology / Natural History (33%), and Clinical Trial Publication (22%).
Hayashi T (2025). [PMID: 41314180](https://pubmed.ncbi.nlm.nih.gov/41314180/). *Georgian medical news*. [Clinical Trial Publication]
Kaur N (2025). [PMID: 40951860](https://pubmed.ncbi.nlm.nih.gov/40951860/). *Journal of mid-life health*. [Case Report / Case Series]
Irie T (2025). [PMID: 40625765](https://pubmed.ncbi.nlm.nih.gov/40625765/). *International cancer conference journal*. [Case Report / Case Series]
Aparajita D (2025). [PMID: 41318519](https://pubmed.ncbi.nlm.nih.gov/41318519/). *World journal of surgical oncology*. [Clinical Trial Publication]
Majumder A (2025). [PMID: 40824725](https://pubmed.ncbi.nlm.nih.gov/40824725/). *Indian journal of pathology & microbiology*. [Epidemiology / Natural History]
Data assembled from 3 of 12 sources · Last updated Sep 18, 2026, 9:49 AM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Luo L (2024). [PMID: 39048446](https://pubmed.ncbi.nlm.nih.gov/39048446/). *Asian journal of surgery*. [Epidemiology / Natural History]
Shen L (2024). [PMID: 39019756](https://pubmed.ncbi.nlm.nih.gov/39019756/). *Asian journal of surgery*. [Epidemiology / Natural History]
Lugata J (2024). [PMID: 39332220](https://pubmed.ncbi.nlm.nih.gov/39332220/). *International journal of surgery case reports*. [Case Report / Case Series]
Derfoufi J (2024). [PMID: 39463652](https://pubmed.ncbi.nlm.nih.gov/39463652/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning cervical carcinosarcoma
Updated Mar 1, 2026
A study published in PubMed evaluates the efficacy of lenvatinib combined with pembrolizumab for treating recurrent endometrial cancer, particularly focusing on nonendometrioid histologies like carcinosarcoma. This research contributes to understanding treatment options for a challenging cancer subtype.